Annovis to Host Corporate Update Webinar on September 2, 2026

Rhea-AI Summary

Annovis (NYSE: ANVS) will host a corporate update webinar with live Q&A on Wednesday, September 2, 2026, at 4:00 p.m. EDT, presented by Founder, President and CEO Maria Maccecchini, Ph.D.. The event will cover recent progress, clinical programs, and upcoming milestones for buntanetap in Alzheimer’s and Parkinson’s disease.

News Explained

The pivotal Alzheimer’s trial is fully enrolled; its readout and regulatory submissions remain expected milestones for 2027.

Annovis reports that its pivotal Phase 3 Alzheimer’s disease trial is fully enrolled, with preparations underway for a top-line readout and regulatory submissions expected in 2027. The disclosed company-level change is a move from enrollment into preparation for those clinical and regulatory steps.

The company also plans to continue the Alzheimer’s program into an open-label study, with first patients expected to join in October 2026; this is a planned next phase rather than a completed study.

For Parkinson’s disease, the open-label study is described as well underway, while discussions with key opinion leaders and the FDA remain ongoing before initiating the Parkinson’s disease dementia program.

Market Reaction – ANVS

+3.71% $1.81

15m delay

+3.71% Vs previous close

$1.81 Last Price

$1.72 $1.83 Day Range

$77.33M Market Cap

0.5x Rel. Volume

Following this news, ANVS has gained 3.71%, reflecting a moderate positive market reaction. The stock is currently trading at $1.81.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The July 7 enrollment announcement was followed by a -2.54% 24-hour reaction, providing a company-sp...

Analysis

The July 7 enrollment announcement was followed by a -2.54% 24-hour reaction, providing a company-specific comparison for this scheduled update. The latest 10-Q reported cash funding expected only into Q4 2026, a material execution risk.

Key Figures

Trial Phase: Phase 3 Expected Readout and Submissions: 2027 Open-Label Study Start: October 2026 +2 more

5 metrics

Trial Phase Phase 3 Pivotal Alzheimer’s disease trial

Expected Readout and Submissions 2027 Top-line data readout and regulatory submissions

Open-Label Study Start October 2026 First patients joining the Alzheimer’s open-label study

Webinar Date September 2, 2026 Corporate update webinar

Webinar Time 4:00 p.m. EDT Corporate update webinar

Historical Context

5 past events · Latest: Aug 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Q2 2026 earnings	Neutral	+2.2%	Phase 3 enrollment and corporate update plans accompanied quarterly loss.
Jul 07	Phase 3 enrollment	Positive	-2.5%	Pivotal Alzheimer’s trial reached 850 patients, but shares declined.
Jul 01	Leadership appointment	Positive	+3.2%	Cheng Fang became chief scientific officer during late-stage program advancement.
May 26	Listing compliance	Positive	-7.6%	NYSE compliance was regained, but shares declined 7.62%.
May 20	Public offering	Negative	+5.2%	Common-stock offering and warrants generated expected gross proceeds of $15.0 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed divergence in three of five events, including positive enrollment and compliance news, while the leadership appointment aligned with a gain.

Key Terms

phase 3, open-label study, top-line data readout

3 terms

phase 3 medical

"a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

open-label study medical

"continue our AD program into an open-label study to generate long-term safety data"

An open-label study is a type of research where both the participants and the researchers know which treatment or intervention is being administered. This transparency can influence the results, making it important for investors to consider potential biases or limitations when evaluating the study’s findings. Understanding this helps assess the reliability of evidence supporting new products or therapies.

top-line data readout medical

"preparations are already underway for the top-line data readout"

A top-line data readout is the initial, high-level summary of a clinical trial’s main results, usually reporting whether primary endpoints were met and giving key safety signals without the full detailed analysis. For investors it matters because it delivers the first clear signal about a drug’s effectiveness or safety—like a score announced after a game—guiding expectations about regulatory progress, future studies, and potential commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

• Date: Wednesday, September 2, 2026
• Time: 4:00 p.m. EDT
• Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
• Registration link

"Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community," commented Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Several key milestones have been reached: our pivotal Phase 3 AD trial is fully enrolled, and preparations are already underway for the top-line data readout and regulatory submissions, both expected in 2027. We also plan to continue our AD program into an open-label study to generate long-term safety data for buntanetap, with first patients joining in October 2026. On the PD side, the open-label study is well underway, and discussions with Key Opinion Leaders and the FDA are ongoing to initiate the Parkinson's disease dementia program. As we move forward, we are committed to keeping our patient community, stockholders, and everyone following our progress informed at every step."

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

When is the Annovis (ANVS) corporate update webinar scheduled for September 2026?

The Annovis corporate update webinar is scheduled for Wednesday, September 2, 2026, at 4:00 p.m. EDT. According to Annovis, the event will include a live Q&A session and cover recent progress, clinical programs, and upcoming milestones for buntanetap.

Who will present during the Annovis (ANVS) corporate update webinar on September 2, 2026?

The webinar will be presented by Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. According to Annovis, she will provide an overview of recent company progress, ongoing clinical programs, and key milestones in Alzheimer’s and Parkinson’s disease.

What topics will Annovis (ANVS) cover in its September 2, 2026 corporate update webinar?

Annovis will cover recent company progress, ongoing clinical programs, and upcoming milestones for buntanetap. According to Annovis, the webinar will also address its fully enrolled pivotal Phase 3 Alzheimer’s trial, open-label study plans, and Parkinson’s disease program developments.

How does Annovis describe the status of its Phase 3 Alzheimer’s disease trial with buntanetap?

Annovis states its pivotal Phase 3 Alzheimer’s disease trial with buntanetap is fully enrolled. According to Annovis, preparations are underway for top-line data readout and regulatory submissions, both expected in 2027, alongside plans for an open-label study starting October 2026.

What are Annovis’ next steps for buntanetap in Parkinson’s disease and Parkinson’s disease dementia?

For Parkinson’s disease, Annovis reports its open-label study is well underway. According to Annovis, discussions with Key Opinion Leaders and the FDA are ongoing to initiate a Parkinson’s disease dementia program as part of its broader neurodegenerative disease strategy.